Plaque psoriasis drug Ilumya approved by FDA

21 March 2018
2019_biotech_test_vial_discovery_big

The US Food and Drug Administration has approved Ilumya (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

The New Drug Application was submitted by India drug major Sun Pharmaceuticals (BSE: 524715), which acquired rights to tildrakizumab from Merck & Co (NYSE: MRK) in September 2014 in exchange for an upfront payment of $80 million. In Europe, Spain’s Almirall (ALM: MC) has been granted development and commercialization rights to the drug by Sun Pharma, which received an initial upfront of $50 million as part of the deal.

Ilumya, which is Sun Pharma’s first biological drug, selectively binds to the p19 subunit of interleukin (IL)-23 and inhibits its interaction with the IL-23 receptor leading to inhibition of the release of pro-inflammatory cytokines and chemokines. The drug will be manufactured by South Korea’s Samsung BioLogics, under a $55.5 million contract.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology